CAS 911208-73-6 manufacturers and suppliers on PharmaCompass

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

CHEMISTRY

Discover Molecule Insights

BUILDING BLOCK

1 Suppliers, 1 End Use APIs, 6 Related Intermediates

1 Suppliers
1 End Use APIs
6 Related Intermediates

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 911208-73-6, Hdp-tenofovir, Cmx157, Cmx-157, 3-(hexadecyloxy)propyl hydrogen ((((r)-1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate, Cmx 157

Molecular Formula

C₂₈H₅₂N₅O₅P

Molecular Weight

569.7 g/mol

InChI Key

SCTJKHUUZLXJIP-RUZDIDTESA-N

FDA UNII

K7J545MEMA

Tenofovir exalidex is under investigation in clinical trial NCT01080820 (A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers).

1 2D Structure

CAS 911208-73-6

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid

2.1.2 InChI

InChI=1S/C28H52N5O5P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-36-19-17-20-38-39(34,35)24-37-25(2)21-33-23-32-26-27(29)30-22-31-28(26)33/h22-23,25H,3-21,24H2,1-2H3,(H,34,35)(H2,29,30,31)/t25-/m1/s1

2.1.3 InChI Key

SCTJKHUUZLXJIP-RUZDIDTESA-N

2.1.4 Canonical SMILES

CCCCCCCCCCCCCCCCOCCCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)O

2.1.5 Isomeric SMILES

CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@H](C)CN1C=NC2=C(N=CN=C21)N)O

2.2 Other Identifiers

2.2.1 UNII

K7J545MEMA

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Cmx 157

2. Cmx-157

3. Cmx157

4. Hdp-tenofovir

5. Hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine

2.3.2 Depositor-Supplied Synonyms

1. 911208-73-6

2. Hdp-tenofovir

3. Cmx157

4. Cmx-157

5. 3-(hexadecyloxy)propyl Hydrogen ((((r)-1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate

6. Cmx 157

7. K7j545mema

8. 9-r-(2-(phosphonomethoxy)propyl)adenine

9. Phosphonic Acid, (((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, Mono(3-(hexadecyloxy)propyl) Ester

10. Hexadecyloxypropyl Tenofovir

11. Unii-k7j545mema

12. Phosphonic Acid, [[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]-, Mono[3-(hexadecyloxy)propyl] Ester

13. Hdp-pmpa

14. Hdp-(r)-pmpa

15. Tenofovir Exalidex(cmx157)

16. Chembl515564

17. Schembl2299893

18. Tenofovir Exalidex [inn]

19. Bdbm77092

20. Tenofovir Exalidex [who-dd]

21. Hexadecyloxypropyl Ester Of Tenofovir

22. Zinc42875215

23. Db14925

24. Hy-109014

25. Cs-0030512

26. J3.616.616i

27. Q27282054

28. Hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine

29. [(1r)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(3-hexadecoxypropoxy)phosphinic Acid

30. [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic Acid

31. 3-(hexadecyloxy)propyl Hydrogen ((((2r)-1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate

32. 3-(hexadecyloxy)propylhydrogen((((r)-1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate

33. Phosphonic Acid, P-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, Mono(3(hexadecyloxy)propyl) Ester

34. Phosphonic Acid, P-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, Mono(3-(hexadecyloxy)propyl) Ester

2.4 Create Date

2007-12-26

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₅₂N₅O₅P
Molecular Weight	569.7 g/mol
XLogP3	6.7
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	25
Exact Mass	569.37060677 g/mol
Monoisotopic Mass	569.37060677 g/mol
Topological Polar Surface Area	135 Å²
Heavy Atom Count	39
Formal Charge	0
Complexity	650
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Anti-HIV Agents

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)

Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)

BUILDING BLOCK

Upload your portfolio for free, ask us